Biotech start-up Ochre Bio relocates to Alexandria Center for Life Science – New York City

Manhattan, NY JLL has completed a sublease for growing U.K.-based biotech company Ochre Bio at 430 East 29^th St. within the Alexandria Center® for Life Science – New York City.

Backed by a $1 billion funding partnership with German pharmaceutical giant Boehringer Ingelheim, Ochre Bio is considered a game-changer in the biotech sector for the way it is rethinking how we understand and treat liver disease, with the potential to save lives and reduce the need for liver transplants. 

It will relocate from the BioLabs incubator at 180 Varick St. to occupy 5,894 s/f of lab and office space on the sixth floor of the West Tower at the Alexandria Center, the research and development campus that serves as the flagship location for New York City's leading life science companies. The Alexandria Center will house Ochre’s late-stage validation facilities, the largest ex-vivo machine perfusion laboratory of human donor livers in the world, where the company’s novel RNA therapies will be validated prior to entering clinical trials.

“We are thrilled to be planting a flag at the Alexandria Center® for Life Science,” said Quin Wills, CEO and founder of Ochre Bio. “A few years ago, we took a bet on NYC as our US site and are now doubling down on one of the world’s most dynamic biotech and clinical hubs. Our new, larger NYC site will support late-stage validation of our therapies as part of our ambitious clinical goals over the next few years.”

Alexandria has been catalyzing and growing the cluster through the development and operation of the city's first and only commercial life science campus at the Alexandria Center for Life Science – New York City and through the company's leading venture investment platform and unparalleled ecosystem-building expertise. Located on Manhattan's East Side Medical Corridor, the Alexandria Center for Life Science?– New York City offers proximity to the city's top academic medical institutions and major hospitals and provides a campus setting with amenities that create a vibrant ecosystem, attract top-tier talent, and bring together high-quality life science companies to translate scientific discoveries into new treatments and cures for patients. 

A JLL team including executive vice president Bill Harvey, senior vice president John Cahill and associate vice president Thomas Burrus, represented both Ochre Bio and the unnamed sublandlord in this transaction. The deal is the second relocation from BioLabs the team has arranged in recent months. In December 2024, they represented next-generation drug discovery platform Waypoint Bio in its lease at Alexandria.

Burrus said, “It’s incredibly rewarding to help cutting-edge companies like Ochre Bio find a home that supports their mission. Securing space for them at the Alexandria Center for Life Science required a deep understanding of both their scientific needs and the competitive life sciences market in New York. Alexandria provides them a collaborative ecosystem and premier facilities designed for high-growth biotech.”